Mutation of the breast cancer susceptibility gene, BRCA2, leads to breast and ovarian cancers. Mechanistic insight into the functions of human BRCA2 has been limited by the difficulty of isolating this large protein (3,418 amino acids). Here we report the purification of full-length BRCA2 and show that it both binds RAD51 and potentiates recombinational DNA repair by promoting assembly of RAD51 onto single-stranded DNA (ssDNA). BRCA2 acts by targeting RAD51 to ssDNA over double-stranded DNA, enabling RAD51 to displace replication protein-A (RPA) from ssDNA and stabilizing RAD51-ssDNA filaments by blocking ATP hydrolysis. BRCA2 does not anneal ssDNA complexed with RPA, implying it does not directly function in repair processes that involve ssDNA annealing. Our findings show that BRCA2 is a key mediator of homologous recombination, and they provide a molecular basis for understanding how this DNA repair process is disrupted by BRCA2 mutations, which lead to chromosomal instability and cancer.
Mutation of the breast cancer susceptibility gene, BRCA2, leads to breast and ovarian cancers. Mechanistic insight into the functions of human BRCA2 has been limited by the difficulty of isolating this large protein (3, 418 amino acids). Here we report the purification of full-length BRCA2 and show that it both binds RAD51 and potentiates recombinational DNA repair by promoting assembly of RAD51 onto single-stranded DNA (ssDNA). BRCA2 acts by targeting RAD51 to ssDNA over double-stranded DNA, enabling RAD51 to displace replication protein-A (RPA) from ssDNA and stabilizing RAD51-ssDNA filaments by blocking ATP hydrolysis. BRCA2 does not anneal ssDNA complexed with RPA, implying it does not directly function in repair processes that involve ssDNA annealing. Our findings show that BRCA2 is a key mediator of homologous recombination, and they provide a molecular basis for understanding how this DNA repair process is disrupted by BRCA2 mutations, which lead to chromosomal instability and cancer.
One of the proposed driving forces behind the tumorigenic process is the onset of genomic instability that, when coupled to repeated rounds of cell division, promotes oncogenesis 1 . A hallmark of human and mouse cells that are mutant for BRCA2 is severe chromosomal instability marked by an accumulation of chromosomal breaks, translocations, exchanges and other abnormal structures 2 . Accordingly, germline mutations in BRCA2 are associated with a highly penetrant incidence of breast and/or ovarian cancer as well as tumours in other tissues and organs 3, 4 . BRCA2 possesses eight highly conserved repeated sequences, termed the BRC repeats, and a carboxy-terminal region that were shown to bind RAD51 (refs 5-7). RAD51 has a central role in recombination, assembling onto single-stranded DNA (ssDNA) as a nucleoprotein filament and catalysing the invasion and exchange of homologous DNA sequences 8,9 . At the cellular level, loss of BRCA2 function results in sensitivity to cross-linking agents, a decrease in homology-directed repair of double-stranded DNA breaks (DSBs), and defects in replication and checkpoint control 2,10-12 . BRCA2 is also required for RAD51-induced focus formation after exposure to DNA-damaging agents 13, 14 . Prior studies using fragments of BRCA2, fusions of the BRC repeats with the DNA-binding domain (DBD) of BRCA2, and analysis of the Ustilago maydis and Caenorhabditis elegans orthologues, Brh2 and BRC-2 respectively, have provided a framework for understanding the mediator role that BRCA2 has in DSB repair by RAD51-driven homologous recombination [15] [16] [17] [18] [19] [20] [21] [22] [23] (see Supplementary Fig. 1 for a model based on this report and the work referenced above). However, the large size of human BRCA2 (3,418 amino acids), difficulty in driving high-level expression, insufficient solubility, and its propensity to degrade, have precluded isolation of the full-length BRCA2 protein and have hampered fuller understanding of its functions. Here, we describe purification of the full-length protein from human cells, and report its biochemical functions with regard to recombinational DNA repair.
Purified BRCA2 binds RAD51 and DMC1
By using a mammalian expression vector (phCMV1) driven by a CMV promoter and by adding two tandem repeats of the maltose binding protein (designated 2XMBP) to the amino terminus of human BRCA2 (470 kDa including the two MBP tags), we expressed significant amounts of protein that could be purified to near homogeneity ( Fig. 1a and Supplementary Fig. 2 ). The identity of full-length BRCA2 was confirmed by western blotting using an antibody to the C-terminal region of BRCA2 (Fig. 1a, lane 4 and Supplementary Fig.  2b, c) , an antibody to the N-terminal MBP tag, and by mass spectrometric analysis. Mass spectrometric analysis of a variable minor band directly below the full length protein confirmed the presence of a truncated BRCA2 species lacking the C terminus. The band near the 50 kDa marker (Fig. 1a , asterisk) was confirmed by mass spectrometry to be b-tubulin. The presence of this contaminant appears not to interfere with any of our in vitro studies. We found that 2XMBP-BRCA2 fully complemented brca2 mutant (VC8) cells ( Fig. 1b and Supplementary Fig. 3 ); therefore, the tag was not removed for the studies reported here. Hereafter, we refer to the N-terminal 2XMBP-tagged version of full length BRCA2 as BRCA2.
Our initial criteria for determining that purified BRCA2 was properly folded and retained biochemical function was to test its ability to bind recombination proteins that were previously reported to interact. We incubated BRCA2 with several purified candidate proteins and used the MBP tag to capture the complexes on amylose beads, and analyse the complexes on SDS-PAGE gels stained with SYPRO Orange, (Fig. 1c, d ). As expected from in vivo pull-down assays and interaction with a fusion protein construct 5, 15, [24] [25] [26] , human RAD51 bound to BRCA2 (Fig. 1c , lane 9). Also in agreement 27 , BRCA2 bound DMC1 (Fig. 1d , lane 5), the meiotic counterpart of RAD51. BRCA2 bound to yeast Rad51 (Fig. 1c , lane 8) but, given the high homology between the two orthologues (,67% identical; 83% homologous 28, 29 ), this is not surprising. BRCA2 did not appreciably bind the Escherichia coli homologue, RecA, (Fig. 1c, lane 7) showing that interaction did not extend to the evolutionarily distant bacterial protein. We also did not detect any significant interaction with human RPA (Fig. 1d , lane 6), despite a report in the literature 30 , E. coli SSB (Fig. 1c , lane 6), or human RAD52 (Fig. 1d, lane 7) .
The BRC repeat defines a RAD51 binding motif whose number varies widely amongst different organisms ranging from one BRC repeat in U. maydis to 15 repeats in Trypanosoma brucei 31 . Human BRCA2 contains eight BRC repeats. Various studies established that most of the human BRC repeats in isolation can bind RAD51 (refs 5, 24-26); however, it remained unclear how many binding sites are occupied within the context of the full-length protein and whether the interaction affinities were comparable. Using known concentrations of purified RAD51 (Fig. 1e , lanes 1-4) and recombinant BRCA2 (Fig. 1e , lanes 12-14) as standards, and staining with SYPRO Orange, we quantified the binding. In the absence of BRCA2, RAD51 did not bind non-specifically to the amylose resin (Fig. 1e, lane 11 ). In the presence of BRCA2 (Fig. 1e , lanes 5-10), the amount of RAD51 bound increased linearly with concentration (indicative of tight binding in the nM range) until about 4.5 (6 0.9) RAD51 molecules were bound per BRCA2 (Fig. 1f ); afterward, a weaker binding (in the mM range) was evident. At the maximum RAD51 concentration attainable, approximately six RAD51 proteins were bound to each BRCA2. The binding of RAD51 to BRCA2 was also examined under buffer conditions identical to those used for DNA strand exchange assays, and similar binding characteristics were found ( Supplementary Fig.  4 ). The protein complexes formed between BRCA2 and RAD51 were not dependent on magnesium or calcium ions, nucleotide cofactors or the presence of DNA (data not shown).
BRCA2 prefers to bind ssDNA over dsDNA
The DNA binding domain of BRCA2 contains both oligonucleotidebinding (OB) folds and a tower domain, which engender BRCA2 with potential sites for binding both ssDNA and dsDNA 16 . Indeed, both the carboxy terminus of BRCA2 and a fusion protein containing BRC repeats 3 and 4 linked to the DNA binding domain of BRCA2 bind both ssDNA and dsDNA 15, 16 . By using electrophoretic mobility shift assays (EMSA), we tested the ability of BRCA2 to bind ssDNA, dsDNA and dsDNA with an ssDNA tail (39 tailed or 59 tailed). BRCA2 bound to all of these substrates; however, those containing ssDNA were strongly preferred over dsDNA ( Fig. 2a, b ). These results are consistent with previous reports on the DNA binding domain of BRCA2 (ref. 15) . A slight preference for tailed DNA over ssDNA was revealed at higher salt concentrations ( Fig. 2c) ; however, the difference was modest. The binding specificity for the various DNA substrates was unaltered when BRCA2 was incubated with RAD51 before binding to the DNA ( Supplementary Fig. 5 ).
BRCA2 stimulates DNA strand exchange by RAD51
An essential function of RAD51 in recombinational DNA repair is its capacity to homologously pair and exchange DNA strands. To promote this process, RAD51 must assemble onto the 39 ssDNA tails generated by resection of DNA breaks. To mimic the DNA intermediate generated after DSB resection in vivo, we used a tailed DNA substrate created by annealing a 42-mer oligonucleotide to a 167mer to create a 42 base pair (bp) dsDNA region followed by a 125 nucleotide 39 ssDNA overhang ( Fig. 3b ; termed 39 tailed DNA). To Supplementary Fig. 8b .
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validate the DNA substrate, we conducted DNA strand exchange assays as a function of RAD51 protein concentration using an optimized in vitro DNA strand exchange protocol ( Supplementary Fig. 6a , c); optimal product formation was at a 1:3 (RAD51:nucleotide) ratio, consistent with the DNA binding stoichiometry of RAD51 (ref. 32 ). However, in vivo, filament assembly conditions are not optimal: RAD51 must compete with RPA for binding to the ssDNA 33, 34 . Furthermore, RAD51 can bind to both ssDNA and dsDNA, but the binding to dsDNA is not productive and, in fact, blocks DNA strand exchange 9, 34 . Thus, DNA strand exchange can be stimulated in at least two mechanistically distinct ways. Initially, to determine whether BRCA2 affects DNA strand exchange, reactions were performed by using an optimal amount of RAD51 but introducing it concurrently to a mixture of 39 tailed DNA and dsDNA. Indeed, as demonstrated in Fig. 3b , c, when RAD51 is permitted to assemble on both ssDNA and dsDNA, DNA strand exchange is reduced to background levels (Fig. 3b , lanes 2 and 10). However, if BRCA2 is incubated with RAD51 before mixing with DNA substrates, this inhibition is alleviated in a concentrationdependent manner (Fig. 3b , lanes 3-8; Fig. 3c ), indicating that BRCA2 directs RAD51 to ssDNA or limits binding to dsDNA, or both. In the presence of RPA, stimulation by BRCA2 is maintained, although the magnitude is reduced (Fig. 3b , lanes 11-16; Fig. 3c ). To confirm that the product did not result from 'melting' of the donor duplex DNA and spontaneous annealing during the de-proteinization step 35 , we performed the same reaction with tenfold excess unlabelled oligonucleotide complementary to the labelled pairing strand in the stop-mix, and the results were unchanged ( Supplementary Fig. 7a , lane 9). The stimulation was ATP-dependent ( Supplementary Fig. 7a , lanes 11 and 12) and did not occur with a heterologous template ( Supplementary Fig. 7a , lane 10); furthermore, BRCA2 alone was unable to promote DNA strand exchange ( Supplementary Fig. 7a , lane 3). These results support a role for BRCA2 in targeting RAD51 to ssDNA, limiting assembly onto the dsDNA partner, or both.
BRCA2 limits assembly of RAD51 on dsDNA
To determine whether BRCA2 slowed or prevented assembly on the dsDNA partner of DNA strand exchange, reactions were performed using a concentration of RAD51 (0.4 mM) sufficient to saturate both the ssDNA and dsDNA present. At such a concentration, DNA strand exchange is inhibited due to binding of excess RAD51 to the dsDNA target 32, 34 (see Supplementary Fig. 6a , lane 5 and Supplementary Fig.  6c ). To optimize filament formation on the ssDNA, BRCA2 and RAD51 were incubated with the 39 tailed ssDNA first, and then the dsDNA was added to initiate the reaction (Fig. 3d) ; however, the excess free RAD51 binds the dsDNA partner and inhibits the reaction ( Supplementary Fig. 8b , lane 1). To eliminate complications from competition with RPA, these reactions were done in the absence of RPA. BRCA2 stimulated DNA strand exchange in a concentrationdependent manner ( Fig. 3e and Supplementary Fig. 8 , lanes 2-6). To provide more direct evidence that BRCA2 prevents nucleation on the dsDNA and targets RAD51 to the 39 tailed DNA, we preincubated BRCA2 and RAD51 and then analysed RAD51-DNA complex formation by either EMSA or the partitioning of RAD51 onto biotinylated 39 tailed DNA in the presence of excess dsDNA (Supplementary Fig. 9 ): BRCA2 prevented binding of RAD51 to dsDNA ( Supplementary Fig. 9b ) and favoured RAD51 binding to the ssDNA ( Supplementary Fig. 9f ). Taken together with the results of the previous section, these data support the idea that BRCA2 recruits RAD51 to ssDNA, likely by virtue of its affinity for ssDNA, and inhibits assembly of RAD51 onto dsDNA.
BRCA2 recruits RAD51 to ssDNA complexed with RPA Previous work using a human BRCA2 polypeptide fusion and U. maydis Brh2 demonstrated the ability of those proteins to promote RAD51 filament formation onto RPA-coated ssDNA 15, 17 . To determine whether the full-length human BRCA2 protein provides a similar avenue for stimulation, we next performed DNA strand exchange assays using an optimal amount of RAD51 but, rather than permitting filament formation on naked ssDNA, the ssDNA was first complexed with RPA ( Fig.  4a ). RAD51 was subsequently introduced in the presence or absence of BRCA2, and finally, the labelled duplex DNA was added to start the reaction. As expected, incubation of the ssDNA with increasing concentrations of RPA before addition of RAD51 severely impaired DNA strand exchange ( Supplementary Fig. 6b, lanes 4-7) . As shown in Fig.  4b , c, increasing amounts of BRCA2 stimulated DNA strand exchange as much as 20-fold, indicating that BRCA2 accelerates formation of the RAD51 nucleoprotein filament at the presynaptic stage of recombination and alleviates the inhibition posed by RPA. Stimulation by BRCA2 occurred at concentrations as low as 2 nM (Fig. 4b, c) , and that were substoichiometric relative to the RAD51 concentrations (approximately 100-fold less than RAD51).
To confirm a presynaptic role for BRCA2, we also performed kinetic analyses of the DNA strand exchange reactions by varying the time that BRCA2 was incubated with RAD51 and the RPA-ssDNA complex, either before ( Supplementary Fig. 10a -c) or after ( Supplementary Fig.  10d -f) addition of homologous dsDNA. BRCA2 imparts a significant stimulation (,20-fold) of DNA strand exchange in as little as one minute after incubation with RAD51 and the RPA-ssDNA complex ( Supplementary Fig. 10c ); only after 60 min does the yield without BRCA2 match that seen with BRCA2 at 1 min.
In contrast to U. maydis Brh2 (ref. 17 ) and the E. coli analogue, RecFOR 36 , which show a strict specificity to act at a 39 ssDNA overhang, stimulation of DNA strand exchange by human BRCA2 was the same for 39 versus 59 tailed DNA (Fig. 4b , compare lanes 3-8 and 11-16, and 4c). This result was consistent with our observation above ( Fig. 2a, b ) that the binding affinity of BRCA2 for 39 tailed DNA and 59 tailed DNA is the same. A bias was also not apparent at sub-stoichiometric concentrations of RAD51 (data not shown) where reduced filament occupancy revealed junction specificity for Brh2 (ref. 17 ). However, we did observe a consistent twofold preference for both 39 and 59 tailed DNA substrates over ssDNA, indicating that stimulation by BRCA2 is modestly greater for a DNA substrate containing a junction of ssDNA with dsDNA ( Fig. 4c ), also consistent with our binding results. These findings demonstrate that BRCA2 possesses the capacity to broadly stimulate RAD51 assembly onto ssDNA with or without a dsDNA junction, and to uniquely promote the assembly onto either 39 or 59 ssDNA tails. 
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BRCA2 did not stimulate RecA ( Fig. 4d and Supplementary Fig.  11b, left panel) , consistent with the failure to pull-down RecA. When RPA was replaced by SSB, BRCA2 could still stimulate DNA strand exchange by RAD51 ( Fig. 4d and Supplementary Fig. 11b , right panel), implying that neither BRCA2 nor RAD51 need to interact directly with the ssDNA-binding proteins. This idea is further bolstered by the lack of interaction between BRCA2 and either SSB or RPA in the pull-down assays (Fig. 1c, d) . This finding is consistent with the behaviour of a human BRCA2 polypeptide fusion 15 but distinct from that of the bacterial RecFOR and fungal Brh2, which require their cognate ssDNA-binding proteins for stimulation 17, 36 . Thus, it seems that direct interactions between human BRCA2, RAD51 and DNA are sufficient to stimulate the ability of RAD51 to gain access to the RPA-or SSB-coated ssDNA and to then displace them as the ensuing nucleoprotein filament is formed and extended.
Our previous work on the BRC repeats demonstrated that they stabilize ssDNA-RAD51 complexes by blocking the ATPase activity of RAD51 (ref. 21) . To gain insight into the mechanism by which BRCA2 stimulates presynaptic complex formation, we measured its effect on the ATPase activity of RAD51. BRCA2 inhibited the ssDNAdependent ATPase activity of RAD51 in a concentration dependent manner to the level seen in the absence of DNA (Fig. 4e) . These results suggest that the same mechanism for RAD51 nucleoprotein filament stabilization ascribed to the BRC repeats applies to BRCA2 21 : namely, full length BRCA2 stabilizes the RAD51 bound to the ssDNA substrate by down-regulating its ATPase activity, a hydrolysis activity which inactivates and turns over the RAD51 protein; however, quantitatively, this control through down-regulation is achieved at much lower concentrations of BRCA2 than the BRC repeats.
BRCA2 cannot anneal RPA-ssDNA complexes
The capability of BRCA2 to accelerate displacement of RPA by RAD51 without the need for a ssDNA/dsDNA junction has some parallels to yeast Rad52 (yRad52) [37] [38] [39] , but human RAD52 lacks this ability to stimulate RPA replacement 40 . However, because yeast lacks a known BRCA2 homologue whereas mammals possess both BRCA2 and RAD52, it is possible that evolutionary changes separated the functions of yRad52 into several mammalian proteins. Another important role of the multi-functional yRad52, and bacterial RecO, is the annealing of complementary ssDNA that is bound by the cognate ssDNA-binding protein 41, 42 ; both the U. maydis and C. elegans BRCA2 orthologues can anneal ssDNA in the presence of RPA 23, 43 . Consequently, we investigated whether BRCA2 or human RAD52 possess a similar capacity. Complementary ssDNA substrates, with or without saturating human RPA, were incubated with BRCA2 or RAD52 and then mixed (Fig. 5a ). Figure 5b shows that in the absence of proteins, spontaneous annealing occurred over time (lanes 2-5; quantification in Fig. 5c ). BRCA2 marginally increased (lanes 6-9), and RAD52 clearly increased the rate of annealing (lanes 10-13). When RPA was added (lanes 15-18), spontaneous annealing was completely blocked. Unlike the U. maydis and C. elegans orthologues 23, 43 , human BRCA2 was unable to overcome this inhibition (lanes [19] [20] [21] [22] , but RAD52 readily annealed the RPA-ssDNA complexes (lanes [23] [24] [25] [26] . In contrast, when substituted for BRCA2, neither human RAD52 nor yeast Rad52 stimulated DNA strand exchange by RAD51 when the ssDNA was complexed with RPA ( Supplementary Fig. 12 ). Taken together, these data show that BRCA2 and human RAD52 have assumed divergent roles in mammalian cells. BRCA2 has taken on the functions that stimulate joint molecule formation and DNA strand exchange, whereas RAD52 provides the ssDNA-annealing functions of recombination 44 .
Discussion
Our results reveal the biochemical functions of full-length human BRCA2, and they establish that BRCA2 augments the functions of RAD51 that are essential for recombinational repair of DNA breaks ( Supplementary Fig. 1 ). Stimulation by BRCA2 is a consequence of several mutually reinforcing effects; BRCA2 (1) enforces binding of RAD51 to ssDNA, (2) accelerates the rate of RPA-displacement from ssDNA by RAD51, (3) inhibits the ATPase activity of RAD51, and (4) limits binding to dsDNA. BRCA2 focuses the assembly of RAD51 onto ssDNA and facilitates the RAD51-mediated displacement of RPA from ssDNA, which is a key regulatory step of DNA pairing. In support of this general concept, the promotion of RAD51 filament formation onto RPA-coated ssDNA was also demonstrated using a different full-length BRCA2 protein expression construct and preparation 45 . By enabling formation of the presynaptic complex, BRCA2 permits progression to the subsequent DNA pairing phase of recombinational DNA repair. Furthermore, by inhibiting the ssDNA-dependent ATP hydrolysis of RAD51, BRCA2 preserves the active and most stable form of RAD51, the ATP-RAD51-ssDNA complex 21, 22 . Because the rate-limiting step in RAD51 nucleoprotein filament assembly is nucleation of the first several monomers of the filament [46] [47] [48] , BRCA2 can act catalytically to stabilize a nucleus by blocking RAD51 self-inactivation and dissociation via its ATPase activity. If the RAD51 molecules bound to BRCA2 do indeed comprise the nucleus, then BRCA2 can stabilize a nascent filament of up to 4-6 RAD51 molecules. Inhibition of ATPase activity was also observed for the C. elegans proteins (Rad51 and BRC-2) 23 , but not for the U. maydis orthologues (Rad51 and Brh2) 17 or the E. coli analogues (RecA and RecFOR) 36 , indicating that this mechanism of stimulating RAD51 function is a late adaption of multicellular organisms. In addition, our results show that BRCA2 prevents or slows the assembly of RAD51 onto duplex DNA, an aspect of RAD51 filament assembly that impairs recombination reactions. Based on previous single-molecule studies with the BRC repeats 21 , we propose that interaction with fulllength BRCA2 slows nucleation of RAD51 onto dsDNA.
An unanticipated feature of human BRCA2 is its ability to bind and stimulate RAD51-mediated DNA strand exchange at regions of ssDNA as well as at ssDNA/dsDNA junctions of either polarity. This capability permits the BRCA2-facilitated loading of RAD51 in both the 59R39 and 39R59 directions. Although most models for BRCA2 function have focused on DSB repair, we note that these a 5′ 
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characteristics are also consistent and suggestive of a role for BRCA2 in the recombinational repair of DNA gaps that occur during DNA replication due to damage in the template ( Supplementary Fig. 1b ). Given that BRCA2 facilitates growth of the filament in either polarity from internal ssDNA regions or from either junction, BRCA2 could readily contribute to daughter strand DNA gap repair as well as DSB repair. It is notable that the lack of polarity in human BRCA2 function differs from analogues such as RecFOR and Brh2, which load RecA and U. maydis Rad51, respectively, specifically onto the 39 overhanging ssDNA 17, 36 .
The absence of a bias for pairing 39-ends by human RAD51 may reflect its underlying intrinsic capability to assemble in both directions 49 . But because resection of a DSB in vivo produces 39 tailed ssDNA, there is no compelling need for polarity enforcement by BRCA2.
Another key difference between the BRCA2 orthologues of U. maydis and C. elegans 23, 43 is that human BRCA2 is unable to anneal ssDNA complexed with RPA, the physiological intermediate of recombination. However, human RAD52 does manifest this capability, implying that in mammalian cells this function is assumed by RAD52. Yet RAD52 cannot stimulate the assembly of RAD51 onto ssDNA complexed with RPA 40 (Supplementary Fig. 12 ), but BRCA2 can. This behaviour of RAD52 is distinct from yRad52 which displays both of these speciesspecific capabilities [37] [38] [39] 41 , explaining the essential role of yRad52 in all recombinational DNA repair processes. Thus, in vertebrates, these functions have separated: BRCA2 targets RAD51 to ssDNA to mediate DNA strand invasion into a duplex donor to produce joint molecules by a distinctive mechanism, whereas RAD52 anneals RPA-ssDNA complexes in steps or pathways of recombinational repair that could include second-end capture in DSB repair, single-strand annealing (SSA), and synthesis-dependent strand annealing. In support of this idea, error-prone repair by SSA is increased in cells lacking functional BRCA2, whereas RAD52 complementation in RAD52 2/2 mouse ES cells augments the SSA pathway 44, 50 . Both in vivo and in vitro studies have clarified the role of BRCA2 in catalysing the delivery of RAD51 to sites of DNA damage. Our work has confirmed and extended prior expectations that the intact human BRCA2 protein mediates the rapid and ordered assembly of the RAD51 protein onto ssDNA, and helps to explain why cells lacking functional BRCA2 would be severely impaired for formation of this critical intermediate in recombinational repair. As a consequence of BRCA2 loss, DNA break repair mediated through template-directed repair from homologous sequences within an intact homologue or sister chromatid would be disrupted, leading to error prone repair and potential chromosomal instability. The ability to purify full-length human BRCA2, a protein directly responsible for genetically predisposing individuals to substantially high risks for cancer, should open a whole new venue for understanding this very large and complex protein.
METHODS SUMMARY
Expression and purification of full-length BRCA2. Human BRCA2 cDNA was cloned into phCMV1 with two repeats of MBP at the N terminus. 293TD cells were transfected and harvested 31 h post-transfection. Extracts were batch bound to amylose resin. The protein was eluted with 10 mM maltose, loaded onto HiTrap Q, and step eluted at 450 mM NaCl. DNA substrates. Oligonucleotides were PAGE-purified. The 39 tailed, 59 tailed and dsDNA were annealed at 1:1 molar ratio, and 32 P-labelled at the 59-end. DNA strand exchange assays. Unless otherwise indicated, reactions were at 37 uC for 30 min with RAD51 (0.22 mM); RPA (0.1 mM); 39 tailed, 59 tailed, or ssDNA (4 nM molecules) and dsDNA (4 nM molecules). Reactions were terminated with proteinase K-SDS, and analysed by electrophoresis (6% polyacrylamide) and phosphor-imaging.
METHODS
Expression and purification of full length BRCA2. The full-length cDNA (10.3 kb) of human BRCA2 was cloned into phCMV1 (Genlantis) along with two tandem repeats of the maltose binding protein (MBP) tag located at the N terminus of BRCA2. All cloning steps were sequence-verified (MCLab) and the final construct was verified by using 15 primers spanning 700 bp regions of the full length BRCA2 cDNA. A PreScission Protease (GE Life Sciences) site was engineered in between the second MBP sequence and the start of the BRCA2 ORF such that both MBP tags could be cleaved by incubation with the PreScission Protease enzyme.
To express this construct, human 293TD cells (a gift from R. Litman) were transiently transfected using TurboFect (Fermentas) and cells were collected 31 h post-transfection. Typically, twenty 15-cm plates containing 70% confluent 293T cells were used for purification. Cells were re-fed with fresh media, Dulbecco's modified Eagle medium 1 10% FBS (Invitrogen), before transfection and 16 h post-transfection. Cells were collected in buffer H: 50 mM HEPES (pH 7.5), 250 mM NaCl, 5 mM EDTA and 1 mM dithiothreitol (DTT) with the addition of 1% Igepal CA-630, 3 mM MgCl 2 , 1 mM ATP, 1 mM PMSF and Protease Inhibitor Cocktail (Roche). The cell suspension was rotated for 20 min and then spun down at 10,000g for 15 min in a Sorval centrifuge (Oakridge tubes) and the supernatant was incubated overnight with 1 ml of amylose resin (New England Biolabs) per 50 ml of cell lysate (washed extensively with buffer H before addition to the supernatant). The amylose resin was then spun down at 2,000g in a swinging bucket rotor (JS 5.3 Beckman), washed once with lysis buffer, and then poured into a disposable plastic column (Pierce) and washed extensively with buffer H. The protein was then eluted with 10 mM maltose in buffer HG: 50 mM HEPES (pH 7.5), 250 mM NaCl, 0.5 mM EDTA, 10% glycerol and 1 mM DTT. These fractions were then pooled and loaded onto a HiTrap Q (GE Life Sciences), washed with buffer HG, and eluted with buffer HG containing 450 mM NaCl (final storage buffer for BRCA2). The full-length BRCA2 protein was verified by western blot with antibodies to both the C terminus of BRCA2 (Ab-2, EMD) and to the N-terminal MBP tag (anti-MBP, Zymed). The concentration of 2XMBP-BRCA2 was determined using an extinction coefficient at 280 nm of 365,160 M 21 cm 21 . The final concentration was adjusted by subtracting the contributions from contaminants, b-tubulin (which ranged from ,10-25% in multiple preparations) and truncated BRCA2 polypeptide (see Fig. 1a , which ranged from ,5-15%), based on SYPRO Orange quantification. The proteins in the Coomassie-stained gel shown in Fig. 1a comprised full-length protein (,85%), truncated BRCA2 (,5%) and tubulin (,10%). Some preparations contained a trace amount of HSP70 as determined by mass spectrometry; however, this contaminant was minimized by the inclusion of 3 mM MgCl 2 and 1 mM ATP in the lysis buffer. We were unable to detect DSS1 in our preparation; based on comparison to known amounts of purified human DSS1 (a gift from W. Heyer), we estimate by Coomassie quantification that the amount of endogenous DSS1 bound to our purified BRCA2 protein is less than 2% (mole DSS1/mole BRCA2). Typical purification yields from twenty 15-cm plates ranged from 50-100 mg.
Contaminant bands were cut out as gel slices from Coomassie-stained gradient (4-15%) SDS-polyacrylamide gels and analysed by mass spectrometry (UC Davis Proteomics Core Facility). Immunodetection of BRCA2. Cell lysates or purified fractions generated from 293TD cells transfected with 2XMBP-FL BRCA2 were run on 6% SDS-polyacrylamide gels, transferred to PVDF membranes overnight, blocked in 5% milk with 13 TBS-T, and incubated with the primary antibody, Ab-2 (EMD), overnight. For immunoprecipitations, lysates were quantified for protein content by Bradford method and 1 mg total protein was used in an immunoprecipitation reaction containing 20 ml anti-BRCA2 (Ab-1, EMD) antibody and 40 ml protein G1 agarose (Santa Cruz Biotechnology). Immunoprecipitations were rocked for 2 h at 4 uC and then washed with buffer H followed by resuspension in 15 ml sample buffer. The samples were heated at 54 uC for 4 min, loaded onto 6% SDS-polyacrylamide gels, and processed for western blotting as described above. A secondary antibody, anti-mouse or anti-rabbit horse radish peroxidase-conjugated (Santa Cruz Biotechnology) was incubated on the membranes for 40 min. Blots were then washed four times and incubated with ECL Plus (Amersham GE healthcare) for 5 min before visualization on a Storm PhosphorImager. Generation of stable cell lines and clonogenic survival assay. The MBP-BRCA2 and 2XMBP-BRCA2 constructs were stably transfected into VC8 (gift from M. Zdienicka) BRCA2 mutant hamster cells, using FuGene6 (Roche) transfection followed by selection in HAM's F10 media (Invitrogen) plus 10% FBS (Invitrogen) containing 1 mg ml 21 G418. To verify expression of BRCA2, total RNA was isolated from VC8 stable cell clones using TRIzol (Invitrogen). Total RNA (1 mg) was used in each RT-PCR (Titanium One-step RT-PCR, Clontech) reaction containing either MBP primer set (RJ-59MBP2XN/RJ-39MBP2XN) to amplify the MBP tag (1.1 kb) or C-terminal primer set (RJ-598269/RJ-39AGEIBRCA2) to amplify the last 0.9 kb of the BRCA2 open reading frame. RT-PCR reactions were run on 1% agarose gel and visualized with ethidium bromide staining on an Alpha Innotech UV imager. To confirm expression of 2XMBP-or MBP-BRCA2 in VC8 cells at the protein level, an immunoprecipitation/western using Ab-1 (EMD) as the immunoprecipitation antibody and Ab-2 (EMD) as the western antibody was performed. We consistently observed higher expression of the 2XMBP-BRCA2 protein compared to MBP-BRCA2 both in stable VC8 clones, as well as in transient transfections of both VC8 and human 293T cells. Clones positive for expression were tested for complementation by clonogenic survival response to mitomycin C. Cells were seeded at plating density of 5 3 10 5 cells in 6-cm dishes. Cells were 50-70% confluent at time of drug treatment. Mitomycin C (Sigma) stock was a 1.5 mM stock solution. For treatment of cells, mitomycin C was diluted in 2 ml HAM's F10 media with no serum at the following concentrations: 0.1 mM, 0.25 mM and 0.5 mM and placed on cells for 1 h. After 1 h incubation, the media was aspirated off, cells were washed with PBS, then trypsinized and resuspended in 2 ml of HAM's F10 1 10% FBS. Cells were counted using a haemocytometer, serially diluted, and plated out in triplicate into 6-well plates. Cells were re-fed with media containing penicillin/ streptomycin (Hyclone) to prevent any contamination during 8 days of cell growth. After 8 days, the cells were removed from the incubator, washed with 0.9% NaCl (saline solution), and stained with crystal violet. Plates were dried overnight and colonies containing 50 or more cells were counted on each plate and the surviving fraction was determined for each drug treatment. Protein affinity pull-downs. Prior to pull-down assays, amylose resin (NEB) was equilibrated with binding buffer B: 50 mM HEPES (pH 7.5), 250 mM NaCl, 0.5 mM EDTA and 1 mM DTT. Purified 2XMBP-BRCA2 (2.4 mg) was incubated with 1 mg purified RAD51, RPA, SSB, RecA, yRad51, DMC1 or RAD52 for 30 min at 37 uC and then batch-bound to 30 ml of amylose resin for 1 h at 4 uC. RAD51 and RPA were purified as described previously 21 . SSB, RecA and yRad51 were purified as described [51] [52] [53] , respectively. RAD52 was a gift from A. Mazin, and the purification of DMC1 (A. Nimonkar) will be described elsewhere. As controls for non-specific binding to the amylose resin, candidate proteins (1 mg) were incubated with amylose resin in the absence of 2XMBP-BRCA2. The complexes were then washed with buffer B containing 0.1% Igepal CA-630 and resuspended in protein sample buffer, heated at 54 uC for 4 min, and loaded onto a 4-15% gradient SDS-polyacrylamide gel (Bio-Rad TGX gel). The gel was run for 1 h at 100 V and stained with SYPRO Orange (Invitrogen) or Coomassie (Bio-safe, Bio-Rad). The protein bands were quantified by ImageQuant software on a Storm 860 PhosphorImager (Molecular Dynamics). The amount of RAD51 pulled down with 2XMBP-BRCA2 in Fig. 1e was determined using standard curves generated from known concentrations of RAD51 and 2XMBP-BRCA2 run in parallel in the same gel. The total input amount of 2XMBP-BRCA2 in each pull-down reaction was 64 nM and the total input amount for RAD51 ranged from 85 nM to 2 mM. The analyses to determine the ratio of RAD51 to 2XMBP-BRCA2 was derived from a fit to a segmented linear regression (GraphPad Prism 5.0b). Electrophoretic mobility shift assays. Oligonucleotide substrates were obtained from either Sigma or IDT (Ultramers) and were purified by polyacrylamide gel electrophoresis (PAGE). The following oligonucleotides were used: RJ-167-mer (59-CTGCTTTATCAAGATAATTTTTCGACTCATCAGAAATATCCGTTTC CTATATTTATTCCTATTATGTTTTATTCATTTACTTATTCTTTATGTTCA TTTTTTATATCCTTTACTTTATTTTCTCTGTTTATTCATTTACTTATTTTG TATTATCCTTATCTTATTTA-39); RJ-59TAIL-167-mer (59-ATTTATTCTAT TCCCTTTATTTTCTCTGTTTATTCATTTACTTATTTTGTATTAATTTCCTA TATTTTTTACTTGTATTTCTTATTCATTTACTTATTTTGTATTATCCTTAT TTATATCCTTTCTGCTTTATCAAGATAATTTTTCGACTCATCAGAAATAT CCG-39); RJ-PHIX-42-1 (59-CGGATATTTCTGATGAGTCGAAAAATTATC TTGATAAAGCAG-39); RJ-Oligo1 (59-TAATACAAAATAAGTAAATGAAT AAACAGAGAAAATAAAG-39); RJ-Oligo2 (59-CTTTATTTTCTCTGTTTATT CATTTACTTATTTTGTATTA-39). To generate the 39 tailed DNA substrate, RJ-167-mer was radio-labelled with 32 P at the 59-end and then annealed at a 1:1 molar ratio to RJ-PHIX-42-1. To generate the 59 tailed DNA substrate, RJ-59TAIL-167-mer was radio-labelled with 32 P at the 59-end and annealed at 1:1 molar ratio to RJ39PHIX-42-1. The dsDNA was generated by radio-labelling RJ-Oligo1 with 32 P at the 59-end and annealing it to RJ-Oligo2. The ssDNA substrate was RJ-167-mer radio-labelled with 32 P at the 59-end.
2XMBP-BRCA2, at the indicated concentrations, was incubated with 0.2 nM (molecules) radio-labelled DNA substrate for 30 min at 37 uC in DNA strand exchange buffer (25 mM Tris acetate (pH 7.5), 1 mM MgCl 2 , 2 mM CaCl 2 , 0.1 mg ml 21 BSA, 2 mM ATP and 1 mM DTT). The reactions were resolved by electrophoresis on a 6% polyacrylamide gel in TAE (40 mM Tris-acetate (pH 7.5), 0.5 mM EDTA) buffer for 70 min at 60 V. The gel was then dried and exposed to a PhosphorImager screen overnight. The screen was scanned on a Molecular Dynamics Storm 840 PhosphorImager and bands quantified using ImageQuant software. The percentage of protein-DNA complexes was calculated as the free radio-labelled DNA remaining in a given lane relative to the protein-free lane, which defined the value of 0% complex (100% free DNA). Where BRCA2 was preincubated with RAD51, the two proteins were mixed at the indicated concentrations at 37 uC for 15 min before addition of the radiolabelled DNA substrate, which was followed by an additional 30 min incubation at 37 uC. DNA strand exchange assays. DNA substrates were generated as described above for the EMSA analysis except that RJ-167-mer and RJ-59TAIL-167-mer were not radio-labelled. The dsDNA donor was generated by first radio-labelling RJ-Oligo1 with 32 P on the 59-end and annealing it to RJ-Oligo2 at a 1:1 molar ratio. The assay buffer contained: 25 mM Tris acetate (pH 7.5), 1 mM MgCl 2 , 2 mM CaCl 2 , 0.1 mg ml 21 BSA, 2 mM ATP and 1 mM DTT. All pre-incubations and reactions were at 37 uC. The DNA substrates and proteins were at the following concentrations unless otherwise indicated in the figure legend: RPA (0.1 mM); RAD51 (0.22 mM); 39 tail, 59 tail or ssDNA (4 nM molecules); and dsDNA (4 nM molecules). Unless a time course was shown, the reaction time was 30 min. Where proteins were omitted, storage buffer was substituted. The protein storage buffer contributed an additional 68 mM NaCl and 4% glycerol to the assay buffer used in the reactions. RecA (0.22 mM) reactions contained 3 mM ATPcS instead of ATP and were performed in 10 mM MgCl 2 in the absence of CaCl 2 . Reactions using SSB (0.1 mM) contained 5 mM MgCl 2. The product yield using RecA alone or hRAD51 alone was 59% and 37%, respectively. The reaction was terminated with Proteinase K in 0.5% SDS for 10 min. The reactions were loaded on a 6% polyacrylamide gel in TAE buffer and electrophoresis was at 60 V for 70 min. The gel was then dried and exposed to PhosphorImager screen overnight. The percentage of DNA strand exchange product was calculated as labelled product divided by total labelled input DNA in each lane. ATP hydrolysis assays. The assay was carried out essentially as described 21 . Briefly, BRCA2 at concentrations 0-100 nM was preincubated with 39 tail DNA (0.9 mM nucleotides) in 10 mL of buffer containing 20 mM Tris-HCl (pH 7.5), 4 mM MgCl 2 , 1 mM DTT, 0.5 mM ATP and 20 mCi ml 21 [c 32 P]-ATP. The reaction was started by adding RAD51 (0.3 mM) or storage buffer, and further incubated at 37 uC for 90 min. Aliquots (2 ml) were spotted onto a polyethyleneimine (PEI) thin layer chromatography (TLC) plate (EMD Chemicals) at each time point. The spots were air-dried and the plates were developed in 1 M formic acid and 0.5 M LiCl. The amount of ATP hydrolyzed was determined from dried plates using a Molecular Dynamics Storm 840 PhosphorImager. The percentage of ATP hydrolysis was quantified using ImageQuant software and any residual signal from the BRCA2-only lanes was subtracted from the RAD51 1 BRCA2 lanes. The results were plotted using GraphPad Prism 5.0b. Single-stranded DNA annealing assays. Cold 167-mer (RJ-167mer, IDT Ultramer, PAGE-purified) at 8 nM (molecules) and 59 radio-labelled 40-mer (RJ-Oligo1, Sigma, PAGE-purified) at 4 nM (molecules) were each incubated separately in 10 ml reactions containing 25 mM Tris acetate (pH 7.5), 1 mM MgCl 2 , and 1 mM DTT for 5 min with or without RPA (100 nM). The 40-mer is complementary to the 167-mer at the 39 end. All incubations were at 37 uC. The oligonucleotides were then incubated with either BRCA2 (40 nM), RAD52 (100 nM) or protein storage buffer for 5 min. The two separate reactions were then mixed and incubated for 1, 5, 15 or 30 min to allow for annealing. At the indicated time points aliquots were removed and added to stop buffer (4 mg ml 21 proteinase K, 1% SDS and 0.4 mM unlabelled 40-mer (RJ-Oligo2)) complementary to RJ-Oligo1 for 15 min. Loading dye was then added to the samples and they were run on 6% polyacrylamide gels in TAE buffer for 1 h at 60 V. The gels were dried onto DEAE (Whatman) paper and exposed to a PhosphorImager screen overnight. The screens were scanned on a Storm 860 system (Molecular Dynamics) and bands quantified using ImageQuant. The percentage of annealed product was calculated as the radio-labelled product divided by the total radiolabelled input DNA in each lane. Biotinylated DNA pull-down assay. An oligonucleotide substrate composed of the same sequence as RJ-PHIX-42-1 but containing a 39 biotin modification (Biotin-TEG) was obtained from Eurofins MWG Operon. The 39 biotin modified oligonucleotide was purified by polyacrylamide gel electrophoresis (PAGE) and annealed at a 1:1 molar ratio to RJ-167-mer to create the biotinylated 39 tailed DNA substrate. RAD51 was preincubated with or without BRCA2 for 15 min at 37 uC in buffer S: 25 mM Tris acetate (pH 7.5), 1 mM MgCl 2 , 0.1 mg ml 21 BSA, 2 mM ATP and 1 mM DTT. The proteins were then added to a mixture of both the biotinylated 39 tailed DNA and a heterologous 90 bp duplex DNA (PAGEpurified Oligo#90: 59-CGGGTGTCGGGGCTGGCTTAACTATGCGGCATC AGAGCAGATTGTACTGAGAGTGCACCATATGCGGTGTGAAATACCGC ACAGATGCGT-39 annealed 1:1 to PAGE-purified Oligo#60: 59-ACGC ATCTGTGCGGTATTTCACACCGCATATGGTGCACTCTCAGTACAATCT GCTCTGATGCCGCATAGTTAAGCCAGCCCCGACACCCG-39) derived from the pUC19 plasmid sequence. The incubation was continued for 5 min at 37 uC followed by capture of the DNA-protein complexes by adding 2.5 ml of prewashed MagnaLink Streptavidin magnetic beads (SoluLink) in buffer S supplemented with 0.1% Igepal CA-630. After binding to the beads at 25 uC for 10 min, the bead complexes were washed with buffer S containing 0.1% Igepal CA-630 and resuspended in 15 ml protein sample buffer, heated at 54 uC for 4 min, and loaded onto a 4-15% gradient SDS-polyacrylamide gel. The amount of RAD51 protein bound and eluted from the biotinylated DNA substrate was determined by western blot using a monoclonal antibody specific to human RAD51 (14B4, Novus).
